Patent: 4,729,957

Summary for Patent: 4,729,957

Title:	Process for manufacture of L-asparaginase from erwinia chrysanthemi
Abstract:	A process for the recovery and purification of L-asparaginase from Erwinia chrysanthemi is disclosed. The process involves the preparation of cellular acetone powder extract followed by either an ion exchange and affinity chromatography purification steps or by affinity chromatography alone. The column eluent is then dialyzed to produce substantially pure L-asparaginase.
Inventor(s):	Lee; Shwu-Maan (Frederick, MD), Ross; John T. (Myersville, MD), Wroble; Marie H. (Mt. Airy, MD)
Assignee:	The United States of America as represented by the Department of Health (Washington, DC)
Application Number:	06/916,796
Patent Claims:	see list of patent claims

United States Patent 4,729,957: Claims Validity, Claim Scope, and U.S. Patent Landscape

What does US 4,729,957 claim, in enforceable terms?

US 4,729,957 claims a multi-step purification process for L-asparaginase produced by Erwinia (spelled “Erwina” in the claims) using an Erwinia cell disruption plus staged clarification and affinity chromatography workflow. Independent claim 1 is a process claim with seven method steps that collectively define what must be performed to infringe. Dependent claims then narrow the organism, process repetition, chromatography mode, resin type, and a specific buffer system.

Independent claim 1 (process definition)

Claim 1 requires all of the following steps in the recited order (or at least as part of the same process sequence, per typical process-claim claim construction):

1. Harvest cells from “both” (the claim text is incomplete in the excerpt, but the structure indicates harvesting cells from an Erwinia culture source).
2. Permealizing the cells by mixing with acetone and passing the acetone/cell mixture through a filter press at least once.
3. Rinsing the acetone/cell cake with buffer in neutral pH range pH 6.5 to 7.5 to remove acetone.
4. Rinsing cells with buffer in alkaline range.
5. Passing cells from step 4 through a cell press to extract the enzyme.
6. Clarifying the enzyme-containing fluid by in-line passage through a filter bag loaded with Cell Debris Remover.
7. Purifying the enzyme on an affinity chromatography column.

Dependent claims (narrowing elements)

• Claim 2: organism used is Erwinia chrysanthemi.
• Claim 3: step 2 performed twice.
• Claim 4: chromatography column is an ion-exchange column (this narrows “affinity chromatography” to an ion-exchange modality, depending on construction).
• Claim 5: chromatography column is an affinity bead column.
• Claim 6: affinity bead column uses Sepharose Fast Flow beads.
• Claim 7: alkaline buffer of step 4 is 10 mM borate at pH 9.5.

How broad or vulnerable is claim scope under U.S. patent standards?

Claim 1 is broad at the level of generic operations (filter press with acetone permeabilization, neutral rinse, alkaline rinse, cell press extraction, in-line filter-bag debris removal, affinity chromatography). It is narrow at the level of required combinations: the claim does not cover any general “asparaginase purification.” It requires this specific process architecture.

Key scope-defining limitations

1. Acetone permeabilization + filter press: The claim requires mixing with acetone and passing the mixture through a filter press at least once.
2. Neutral pH 6.5 to 7.5 acetone removal: A defined neutral-pH rinse step is required.
3. Alkaline rinse plus cell press extraction: The claim requires alkaline rinsing prior to mechanical extraction through a cell press.
4. In-line clarification with a filter bag loaded with a “Cell Debris Remover”: This is a structured clarification element.
5. Affinity chromatography as the final purification stage.

Main vulnerability: prior art and obviousness risk from standard unit operations

Each step reflects known unit operations in enzyme purification (acetone permeabilization/disruption, staged pH rinses, mechanical extraction, clarification filters, chromatography). For obviousness, the critical question is whether a skilled person would have combined these steps to reach L-asparaginase purification from Erwinia using an affinity chromatography polish.

Claim 1’s enforceability hinges on whether:

• the specific sequence and pH-defined rinses were not taught together, or
• the acetone/filter-press permeabilization with downstream cell press extraction and affinity chromatography was not an expected combination.

Because claim 1 is a process claim with multiple common purification steps, the landscape risk is that novelty sits in the specific combination rather than in any single step.

Potential claim construction friction points

• “Affinity chromatography column” vs “ion-exchange column”: Claim 4 depends on claim 1 but states the chromatography column is an ion-exchange column. If ion exchange is construed as a distinct chromatographic category from affinity chromatography, that dependence could create internal narrowing tension. Courts often construe dependent claims as further limiting the independent claim, but they still must read coherently.
• “Cell Debris Remover”: This term can be a product/process step tied to a known filtration aid or adsorbent cartridge concept. Overly generic language can broaden the claim, but it can also invite non-infringement arguments by showing different clarification chemistry or device structure.

What would likely satisfy anticipation or obviousness tests?

Without the full specification, the most defensible evaluation is to map the claim to typical enzyme purification workflows and identify what prior art would need to disclose to invalidate or narrow.

Anticipation (35 U.S.C. §102) pathway

To anticipate claim 1, a single prior art reference must disclose a process that includes:

• acetone permeabilization with a filter press,
• neutral rinse at pH 6.5 to 7.5 to remove acetone,
• alkaline rinse (with a defined alkaline range, even if not exactly pH 9.5 unless claimed in claim 7),
• cell press extraction,
• in-line filter bag clarification loaded with a debris remover,
• affinity chromatography purification of L-asparaginase from an Erwinia source.

The specificity of the filter press + acetone + pH-defined rinse + debris-remover clarification combo makes a strict anticipation hit less likely unless the exact workflow is copied.

Obviousness (35 U.S.C. §103) pathway

Obviousness is more plausible because the claim reads as a combination of standard enzymatic purification operations. The strongest argument for invalidity would show:

• known permeabilization/disruption methods for Erwinia or similar bacterial hosts using acetone and mechanical filtration,
• known staged buffer rinses (neutral to remove acetone; alkaline to prepare cells for extraction),
• known extraction using mechanical cell presses,
• known clarification using filter aids and debris removal,
• known use of affinity chromatography (or a known need to use affinity polishing for asparaginase impurities).

Where the obviousness case strengthens is if prior art teaches the same goal: high-purity L-asparaginase with reduced protease/host impurities, and teaches affinity polishing as a conventional final step.

Dependent claim landscape: where precision narrows infringement risk

Dependent claims increase specificity and typically reduce the universe of infringers. They also increase invalidity leverage if the specific features were widely used.

Claim 2 (Erwinia chrysanthemi)

This is a straightforward narrowing to a particular organism. If prior art covers L-asparaginase purification from Erwinia species broadly (e.g., Erwinia chrysanthemi) using similar processing, the dependent claim is vulnerable to obviousness or anticipation depending on disclosure specificity.

Claim 3 (step 2 performed twice)

“Performed twice” adds operational specificity. Prior art that once describes the acetone/filter press step may not anticipate this exact repetition, but obviousness could still apply if duplicating the permeabilization step is routine for yield or purity.

Claim 4 (ion-exchange column) and claim 5-6 (affinity bead column; Sepharose Fast Flow)

These claims constrain the final chromatographic polish:

• Ion exchange is a broader “mode” category; Sepharose Fast Flow is a concrete resin.
• If Sepharose Fast Flow with a specific ligand is used in published workflows, claim 6 may face higher invalidity risk for novelty.

Claim 7 (10 mM borate pH 9.5 alkaline rinse)

This is the most precise limitation. It targets a specific buffer identity and pH. For infringement, this forces the exact or functionally equivalent condition as construed by claim scope. For invalidity, it requires a prior art disclosure that uses borate buffer at ~pH 9.5 and 10 mM in this context.

How does the patent landscape likely shape freedom-to-operate?

US 4,729,957’s claim style suggests it covers an early/mid-generation purification process architecture. In the U.S. market, later asparaginase manufacturing often uses:

• different lysis/disruption methods (e.g., sonication, high-pressure homogenization),
• different clarification trains (centrifugation, depth filtration),
• and different chromatography modalities (ion exchange + affinity with specific ligands, often under more tightly controlled GMP conditions).

Even if later processes avoid acetone/filter press permeabilization or avoid the neutral-to-alkaline rinse sequence with cell press extraction, they can fall outside claim 1.

Landscape risk profile

• High risk for facilities that still use acetone permeabilization with mechanical filtration plus stage rinsing and cell-press extraction as a core step, and then polish via affinity chromatography.
• Lower risk if the process uses alternative disruption (non-acetone permeabilization, no filter press), or uses centrifugation and chromatography trains that diverge from the claim sequence (no affinity bead column; different polishing resin; different buffer systems).

What infringement arguments are plausible?

Direct infringement (all steps)

To establish direct process infringement, the accused process must practice the whole combination of claim 1 steps. That makes “partial overlap” insufficient.

Design-around levers

Common design-around targets against claim 1:

• remove acetone/filter press permeabilization,
• replace the neutral pH 6.5-7.5 rinse,
• replace cell press extraction (use a different extraction mechanism),
• change the clarification device/loaded “Cell Debris Remover” step into an incompatible clarification strategy,
• replace affinity chromatography with non-affinity chromatography or a different resin class.

Against claim 7 specifically:

• alter borate buffer identity and/or pH and molarity.

Against claim 6 specifically:

• change resin from Sepharose Fast Flow to another bead system or alter ligand chemistry such that the resin is not “Sepharose Fast Flow beads.”

What invalidity arguments are plausible in litigation?

For claim 1

• Obviousness: combine known acetone permeabilization and filtration with known enzyme extraction workflows and known final affinity purification for L-asparaginase.
• Lack of definitional novelty: if “Cell Debris Remover” and “affinity chromatography” are broadly known, the combination may be attacked as routine.

For dependent claims 7 and 6

• If prior art discloses borate buffer at pH 9.5 for enzyme extraction/conditioning, claim 7 is vulnerable.
• If prior art discloses Sepharose Fast Flow in asparaginase affinity purification, claim 6 is vulnerable.

Key Takeaways

• US 4,729,957 is a combination process claim. Infringement requires practicing the complete method architecture of claim 1, not just purifying L-asparaginase.
• The most enforceable levers are the acetone/filter press permeabilization, the pH-defined neutral rinse (6.5-7.5), the alkaline rinse prior to cell press extraction, the in-line debris-remover filter bag, and affinity chromatography as the final step.
• Dependent claims narrow sharply to Erwinia chrysanthemi, repetition of permeabilization, ion-exchange vs affinity mode, and specifically Sepharose Fast Flow beads and 10 mM borate at pH 9.5.
• Validity risk is highest under obviousness because the claim reads as a sequencing of standard unit operations; the strongest defense is that the prior art did not teach this exact combination and order for L-asparaginase from Erwinia with these defining conditions.

FAQs

1. Does US 4,729,957 protect any L-asparaginase purification process in the U.S.?
   No. It protects the specific multi-step process defined in claim 1, including acetone/filter press permeabilization, pH-specific rinses, cell press extraction, debris-remover clarification, and affinity chromatography.

2. If a manufacturer uses affinity chromatography but not acetone/filter press permeabilization, is that outside the claim?
   Yes, because claim 1 requires the acetone/filter press permeabilization and subsequent rinsing/extraction sequence.

3. Are the dependent claims more difficult to infringe than claim 1?
   Yes. Dependent claims add specific constraints (organism, repetition, ion-exchange vs affinity, Sepharose Fast Flow beads, and borate pH 9.5 buffer).

4. Which single feature most strongly differentiates claim 1 from generic enzyme purification?
   The defined combination of acetone permeabilization through a filter press, a neutral rinse at pH 6.5 to 7.5 to remove acetone, followed by alkaline rinsing and extraction via cell press, plus the specific clarification and affinity chromatography steps.

5. What is the biggest litigation fault line in this patent?
   Whether prior art disclosed the same integrated workflow as a non-obvious combination for Erwinia L-asparaginase purification, or whether it taught enough of the sequence that only routine optimization remained.

---

References (APA)

No specific external sources were provided with the request, and no patent text, prosecution history, or citation list for US 4,729,957 was included.

Details for Patent 4,729,957

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978	4,729,957	2006-10-08
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	November 18, 2011	4,729,957	2006-10-08